IN THE CLAIMS:

1. (Amended) A method for preparing a pharmaceutical composition for reducing an unwanted T-cell response in a host, comprising:

culturing peripheral blood monocytes from said host to differentiate into dendritic cells[,];

activating said dendritic cells in the presence of a glucocorticoid hormone; and

loading said dendritic cells with an antigen against which said T-cell response is to be reduced.

4. (Amended) A method for reducing an unwanted T-cell response in a host, comprising:

culturing peripheral blood monocytes from said host to differentiate into dendritic cells[,];

activating said dendritic cells in the presence of a glucocorticoid hormone [and];

loading said dendritic cells with an antigen against which said T-cell response is to be reduced;

forming a composition comprising said dendritic cells loaded with an antigen against which said T-cell response is to be reduced; and

administering said composition to said host.

5. (Amended) [A] The method according to claim 1, [3 or 4 whereby said activation is done through] wherein activating said dendritic cells in the presence of a glucocorticoid hormone comprises activating said dendritic cells through a CD40 receptor.

6. (Amended) [A] The method according to claim 5 [whereby said activation], wherein activating said dendritic cells through a CD40 receptor involves incubation of the dendritic cells with [either] a substance selected from a group consisting of a CD8-40L fusion protein, a trimeric form of CD40L consisting of CD40L molecules to which a modified leucine zipper has been attached, anti-CD40 antibodies, [or] and cells that express CD40L.

7. (Amended) [A] The method according to claim 5 [whereby said activation], wherein activating said dendritic cells through a CD40 receptor involves incubation of the dendritic cells with a substance selected from a group consisting of lipopolysaccharide (LPS) [or] and polyI/C.

8. (Amended) [A] The method according to claim 1, [3 -7 whereby] further comprising infecting said dendritic cells [are infected] with one or more recombinant viruses encoding [the antigen(s)] at least one antigen of interest before activating said dendritic cells in the presence of a glucocorticoid hormone.

9. (Amended) [A] The method according to claim 1, [3-8 whereby] further comprising incubating said dendritic cells [are incubated] with [one or more recombinant proteins or large (> 20 amino acids) synthetic] at least one peptide representing [the antigen(s)] at least one antigen of interest before activating said dendritic cells in the presence of a glucocorticoid hormone.

10. (Amended) [A] The method according to claim 1, [3-9 whereby] further comprising incubating said dendritic cells [are incubated] with cells [or cell homogenate] containing [the antigen(s)] at least one antigen of interest before activating said dendritic cells in the presence of a glucocorticoid hormone.

11. (Amended) [A] The method according to claim 1, [3-10 whereby said dendritic cells are loaded] wherein loading said dendritic cells with an antigen against which said T-cell response is to be reduced comprises loading said dendritic cells with at least one synthetic [peptide(s)] peptide representing [the antigen(s)] at least one antigen of interest after activating said dendritic cells in the presence of a glucocorticoid hormone.

12. (Amended) [A] The method according to claim 1, [3-11 whereby said dendritic cells, after activation] wherein activating said dendritic cells in the presence of a glucocorticoid

hormone[,] comprises activating said dendritic cells such that said dendritic cells secrete interleukin-10.

13. (Amended) A method for obtaining a dendritic cell capable of tolerising a T-cell for an antigen, comprising:

providing said dendritic cell with a glucocorticoid hormone[,];

activating said dendritic cell; and

providing said dendritic cell with said antigen.

14. (Amended) [A] The method according to [anyone of claims 1, 3-13,] claim 13, wherein providing said dendritic cell with a glucocorticoid hormone comprises providing said dendritic cell [and/or a precursor thereof is provided] with said glucocorticoid hormone in vitro.

15. (Amended) [A] The method according to [anyone of claim 1, 3-14,] claim 1, wherein said T-cell is a T-helper cell.

16. (Amended) An isolated dendritic cell [prepared according to anyone of claims 1, 3-15] capable of functionally modifying [an antigen-specific] a T-cell [with respect to the response to said antigen] specific to an antigen such that the response of said T-cell to said antigen is altered.

17. (Amended) A method for functionally modifying [an antigen-specific] a T-cell specific to an antigen, comprising:

providing [an] a dendritic cell [according to claim 16 with said antigen]capable of functionally modifying said T-cell such that the response of T-cell to said antigen is altered; and

co-cultivating said T-cell and said dendritic cell.

18. (Amended) [A] The method according to claim 17, wherein [said] co-cultivating said T-cell and said dendritic cell comprises co-cultivating said T-cell and said dendritic cell [is

performed] in vitro.

19. (Amended) [A] The method according to claim 17 [or claim 18], further comprising multiplying said functionally modified T-cell.

20. (Amended) An isolated functionally modified T-cell [obtainable by a method according to anyone of claims 17-19] produced by the process of claim 17 that is capable, upon administration to a host, of reducing an unwanted immune response.

22. (Amended) A pharmaceutical composition comprising [an dendritic cell according to claim 16 and/or a functionally modified T-cell according to claim 20] a cell selected from a group consisting of a dendritic cell capable of functionally modifying a T-cell specific to an antigen such that the response of said T-cell to said antigen is altered and a functionally modified T-cell capable of reducing an unwanted immune response upon administration to a host.

24. (Amended) A method for the treatment of an individual suffering from or at risk of suffering from a disease associated with at least part of the immune system of said individual, the method comprising:

providing said individual with [an] a cell selected from a group consisting of a dendritic cell [according to claim 16 and/or] capable of functionally modifying a T-cell specific to an antigen such that the response of said T-cell to said antigen is altered and a functionally modified T-cell [according to claim 20] capable of reducing an unwanted immune response upon administration to a host.

25. (Amended) [A] The method according to claim 24, wherein [said dendritic cell and or said T-cell] providing said individual with a cell comprises providing a cell that is derived from an HLA-matched donor.

26. (Amended) [A] The method according to claim 24, wherein [said dendritic cell